JP6930762B2 - ヒトPD−1をノックダウンしたsiRNA、組換え発現CAR−Tベクターおよびその構築方法と使用 - Google Patents
ヒトPD−1をノックダウンしたsiRNA、組換え発現CAR−Tベクターおよびその構築方法と使用 Download PDFInfo
- Publication number
- JP6930762B2 JP6930762B2 JP2019538555A JP2019538555A JP6930762B2 JP 6930762 B2 JP6930762 B2 JP 6930762B2 JP 2019538555 A JP2019538555 A JP 2019538555A JP 2019538555 A JP2019538555 A JP 2019538555A JP 6930762 B2 JP6930762 B2 JP 6930762B2
- Authority
- JP
- Japan
- Prior art keywords
- seq
- lentivirus
- cells
- sequence encoding
- expression vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000013598 vector Substances 0.000 title claims description 73
- 108020004459 Small interfering RNA Proteins 0.000 title claims description 43
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 title claims description 14
- 238000003259 recombinant expression Methods 0.000 title claims description 14
- 238000010276 construction Methods 0.000 title claims description 6
- 102000048362 human PDCD1 Human genes 0.000 title claims description 4
- 210000004027 cell Anatomy 0.000 claims description 141
- 241000713666 Lentivirus Species 0.000 claims description 87
- 239000013612 plasmid Substances 0.000 claims description 53
- 108700010039 chimeric receptor Proteins 0.000 claims description 52
- 108090000623 proteins and genes Proteins 0.000 claims description 50
- 230000014509 gene expression Effects 0.000 claims description 42
- 239000013604 expression vector Substances 0.000 claims description 29
- 206010028980 Neoplasm Diseases 0.000 claims description 27
- 238000004806 packaging method and process Methods 0.000 claims description 27
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 24
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 24
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 24
- 238000013518 transcription Methods 0.000 claims description 24
- 230000035897 transcription Effects 0.000 claims description 24
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 20
- 239000006228 supernatant Substances 0.000 claims description 19
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 16
- 238000003776 cleavage reaction Methods 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 230000007017 scission Effects 0.000 claims description 15
- 230000017188 evasion or tolerance of host immune response Effects 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 11
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 10
- 102000014450 RNA Polymerase III Human genes 0.000 claims description 10
- 108010078067 RNA Polymerase III Proteins 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 230000007246 mechanism Effects 0.000 claims description 10
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 9
- 230000006044 T cell activation Effects 0.000 claims description 9
- 238000013461 design Methods 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 9
- 230000002255 enzymatic effect Effects 0.000 claims description 9
- 230000001124 posttranscriptional effect Effects 0.000 claims description 9
- 230000006798 recombination Effects 0.000 claims description 9
- 230000001105 regulatory effect Effects 0.000 claims description 9
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 8
- 241001492404 Woodchuck hepatitis virus Species 0.000 claims description 8
- 238000010828 elution Methods 0.000 claims description 8
- 239000005090 green fluorescent protein Substances 0.000 claims description 8
- 230000000977 initiatory effect Effects 0.000 claims description 8
- 238000005215 recombination Methods 0.000 claims description 8
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 7
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 7
- 230000005540 biological transmission Effects 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 7
- 102000005962 receptors Human genes 0.000 claims description 7
- 108020003175 receptors Proteins 0.000 claims description 7
- 230000010076 replication Effects 0.000 claims description 7
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 6
- 208000034578 Multiple myelomas Diseases 0.000 claims description 5
- 230000035772 mutation Effects 0.000 claims description 5
- 239000013642 negative control Substances 0.000 claims description 5
- 230000003612 virological effect Effects 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 230000003321 amplification Effects 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 230000002779 inactivation Effects 0.000 claims description 4
- 230000003834 intracellular effect Effects 0.000 claims description 4
- 238000005342 ion exchange Methods 0.000 claims description 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 4
- 238000000967 suction filtration Methods 0.000 claims description 4
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims description 3
- 206010018338 Glioma Diseases 0.000 claims description 3
- 102000018697 Membrane Proteins Human genes 0.000 claims description 3
- 108010052285 Membrane Proteins Proteins 0.000 claims description 3
- 238000004113 cell culture Methods 0.000 claims description 3
- 239000012228 culture supernatant Substances 0.000 claims description 3
- 239000003480 eluent Substances 0.000 claims description 3
- 208000029824 high grade glioma Diseases 0.000 claims description 3
- 201000011614 malignant glioma Diseases 0.000 claims description 3
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims description 3
- 238000001179 sorption measurement Methods 0.000 claims description 3
- 241000702421 Dependoparvovirus Species 0.000 claims description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 2
- 229960000723 ampicillin Drugs 0.000 claims description 2
- 230000000139 costimulatory effect Effects 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 238000010367 cloning Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 239000012634 fragment Substances 0.000 description 30
- 239000002609 medium Substances 0.000 description 29
- 239000000047 product Substances 0.000 description 28
- 239000000243 solution Substances 0.000 description 26
- 241000700605 Viruses Species 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 238000000246 agarose gel electrophoresis Methods 0.000 description 16
- 238000005259 measurement Methods 0.000 description 16
- 108020004999 messenger RNA Proteins 0.000 description 16
- 238000003197 gene knockdown Methods 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 15
- 239000012636 effector Substances 0.000 description 14
- 239000011543 agarose gel Substances 0.000 description 13
- 239000002158 endotoxin Substances 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 230000002147 killing effect Effects 0.000 description 13
- 238000011084 recovery Methods 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 11
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 11
- 101150058049 car gene Proteins 0.000 description 11
- 239000000499 gel Substances 0.000 description 11
- 238000012163 sequencing technique Methods 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 230000003584 silencer Effects 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 238000010586 diagram Methods 0.000 description 9
- 238000012546 transfer Methods 0.000 description 9
- 239000012528 membrane Substances 0.000 description 8
- 230000019491 signal transduction Effects 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 108010074708 B7-H1 Antigen Proteins 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 241000204031 Mycoplasma Species 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000009169 immunotherapy Methods 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 5
- 230000009368 gene silencing by RNA Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 229910021642 ultra pure water Inorganic materials 0.000 description 5
- 239000012498 ultrapure water Substances 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 239000002033 PVDF binder Substances 0.000 description 4
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 4
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 4
- 230000006052 T cell proliferation Effects 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 description 4
- 230000009102 absorption Effects 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000001994 activation Methods 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 3
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 3
- 238000012404 In vitro experiment Methods 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 108091007744 Programmed cell death receptors Proteins 0.000 description 3
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 108010083359 Antigen Receptors Proteins 0.000 description 2
- 102000006306 Antigen Receptors Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 description 2
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 239000006142 Luria-Bertani Agar Substances 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- 101710149951 Protein Tat Proteins 0.000 description 2
- 108091030071 RNAI Proteins 0.000 description 2
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000004873 anchoring Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 108091006004 biotinylated proteins Proteins 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000007783 downstream signaling Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000005965 immune activity Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 229960003301 nivolumab Drugs 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 238000011357 CAR T-cell therapy Methods 0.000 description 1
- 238000011523 CAR-T cell immunotherapy Methods 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 206010050551 Lupus-like syndrome Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 101710094000 Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 102000004167 Ribonuclease P Human genes 0.000 description 1
- 108090000621 Ribonuclease P Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 230000033540 T cell apoptotic process Effects 0.000 description 1
- 241000030538 Thecla Species 0.000 description 1
- 102000002015 Transforming Protein 1 Src Homology 2 Domain-Containing Human genes 0.000 description 1
- 108010040625 Transforming Protein 1 Src Homology 2 Domain-Containing Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000011467 adoptive cell therapy Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 230000012820 cell cycle checkpoint Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- -1 either CaCl 2 Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000003208 gene overexpression Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000002625 monoclonal antibody therapy Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 208000028466 reproductive system neoplasm Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001743 silencing effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Description
a. 配列番号41および配列番号42で示されるヌクレオチド配列、
b. 配列番号43および配列番号44で示されるヌクレオチド配列、
c. 配列番号45および配列番号46で示されるヌクレオチド配列、
d. 配列番号47および配列番号48で示されるヌクレオチド配列、
e. 配列番号49および配列番号50で示されるヌクレオチド配列、
f. 配列番号51および配列番号52で示されるヌクレオチド配列、
g. 配列番号53および配列番号54で示されるヌクレオチド配列。
さらに、a. 配列番号41および配列番号42で示されるヌクレオチド配列が好ましい。
一.材料
1.レンチウイルス骨格プラスミドpLenti-3G silencer、レンチウイルスパッケージングプラスミドpPac-GP、pPac-Rおよび膜タンパク質プラスミドpEnv-G、HEK293T/17細胞、相同組換え酵素、Oligo Annealing BufferはS&E (Shanghai) BIO-PHARMACEUTICAL TECHNOLOGY CO.,LTD.によって提供された。
EF1α-F:5’-ATTCAAAATTTTATCGATGCTCCGGTGCCCGTCAGT-3’ (配列番号25)
EF1α-R:5’-TCACGACACCTGAAATGGAAGA-3’ (配列番号26)
CD8 leader-F:5’-GGTGTCGTGAGGATCCGCCACCATGGCCTTACCAGTGACCGC-3’
(配列番号27)
CD8 leader-R:5’-GTGTCATCTGGATGTCCGGCCTGGCGGCGTG-3’(配列番号28)
VL-F:5’- CACGCCGCCAGGCCGGACATCCAGATGACCCAGAGCC -3’(配列番号29)
VL-R:5’- ACGCTTGATCTCCAGTTTGGT -3’(配列番号30)
OLC-VH-F:5’- ACTGGAGATCAAGCGTGGTGGCGGTGGCTCGGGCGGTGGTGGGTCGG
GTGGCGGCGGATCTCAGGTGCAGCTGGTCCAGAG -3’(配列番号31)
VH-R:5’- GCTGGACACGGTCACTAGTGTG -3’(配列番号32)
CD8 Hinge-F:5’- AGTGACCGTGTCCAGCACCACGACGCCAGCGCC -3’(配列番号33)
CD8 Hinge-R:5’-GTAGATATCACAGGCGAAGTCCA-3’(配列番号34)
CD8 Transmembrane-F:5’-CGCCTGTGATATCTACATCTGGGCGCCCTTGGC-3’(配列番号35)
CD8 Transmembrane-R:5’-TCTTTCTGCCCCGTTTGCAGTAAAGGGTGATAACCAGTG- 3’(配列番号36)
CD137-F:5’-AAACGGGGCAGAAAGAAACTC-3’(配列番号37)
CD137-R:5’-TGCTGAACTTCACTCTCAGTTCACATCCTCCTTCTTCTTC-3’(配列番号 38)
TCR-F:5’-AGAGTGAAGTTCAGCAGGAGCG-3’(配列番号39)
TCR-R:5’-GGAGAGGGGCGTCGACTTAGCGAGGGGGCAGGGC-3’(配列番号40)
siRNA1453-F:5’- CCGGCTAAACTGGTACCGCATGAGCCTCGAGTCATGCGGTACCAGT
TTAGCATTTTTTG -3’(配列番号41)
siRNA1453-R:5’- AATTCAAAAAATGCTAAACTGGTACCGCATGACTCGAGGCTCATGC
GGTACCAGTTTAG -3’(配列番号42)
siRNA1454-F:5’- CCGGCATTGTCTTTCCTAGCGGAATCTCGAGTCCGCTAGGAAAGAC
AATGGTTTTTTTG -3’(配列番号43)
siRNA1454-R:5’- AATTCAAAAAAACCATTGTCTTTCCTAGCGGACTCGAGATTCCGCT
AGGAAAGACAATG -3’(配列番号44)
siRNA1455-F:5’- CCGGAGGCGCAGATCAAAGAGAGTTCTCGAGCTCTCTTTGATCTGC
GCCTTGTTTTTTG -3’(配列番号45)
siRNA1455-R:5’- AATTCAAAAAACAAGGCGCAGATCAAAGAGAGCTCGAGAACTCTC
TTTGATCTGCGCCT -3’(配列番号46)
siRNA1456-F:5’- CCGGCCCTGTGGTTCTATTATATTACTCGAGATATAATAGAACCACAG
GGAATTTTTTG -3’(配列番号47)
siRNA1456-R:5’- AATTCAAAAAATTCCCTGTGGTTCTATTATATCTCGAGTAATATAATA
GAACCACAGGG -3’(配列番号48)
siRNA1457-F:5’- CCGGGGAACCCATTCCTGAAATTATCTCGAGAATTTCAGGAATGGGT
CCAATTTTTTG -3’(配列番号49)
siRNA1457-R:5’- AATTCAAAAAATTGGAACCCATTCCTGAAATTCTCGAGATAATTTCA
GGAATGGGTTCC -3’(配列番号50)
siRNA1458-F:5’- CCGGCAGGCCTAGAGAAGTTTCAGGCTCGAGTGAAACTTCTCTAGG
CCTGCATTTTTTG -3’(配列番号51)
siRNA1458-R:5’- AATTCAAAAAATGCAGGCCTAGAGAAGTTTCACTCGAGCCTGAAA
CTTCTCTAGGCCTG -3’(配列番号52)
siRNA1459-F:5’- CCGGCAGGACTCATGTCTCAATGCCCTCGAGCATTGAGACATGAGT
CCTGTGTTTTTTG -3’(配列番号53)
siRNA1459-R:5’- AATTCAAAAAACACAGGACTCATGTCTCAATGCTCGAGGGCATTGA
GACATGAGTCCTG -3’(配列番号54)
siRNA1460-F:5’- CCGGTTCTCCGAACGTGTCACGTCTCGAGACGTGACACGTTCGGAG
AATTTTTTG -3’(配列番号55)
siRNA1460-R:5’- AATTCAAAAAATTCTCCGAACGTGTCACGTCTCGAGACGTGACACG
TTCGGAGAA -3’(配列番号56)
PD-1-QPCR-F:5’- TGCAGCTTCTCCAACACAT -3’(配列番号57)
PD-1-QPCR-R:5’- CTTGTCCGTCTGGTTGCT -3’(配列番号58)
WPRE-QPCR-F:5’-CCTTTCCGGGACTTTCGCTTT-3’(配列番号59)
WPRE-QPCR-R:5’-GCAGAATCCAGGTGGCAACA-3’(配列番号60)
Actin-QPCR-F:5’-CATGTACGTTGCTATCCAGGC-3’(配列番号61)
Actin-QPCR-R:5’-CTCCTTAATGTCACGCACGAT-3’(配列番号62)
CAR-QPCR-F:5’-GACTTGTGGGGTCCTTCTCCT-3’(配列番号63)
CAR-QPCR-R:5’-GCAGCTACAGCCATCTTCCTC-3’(配列番号64)
図4を参照すると、本発明に係る組換えレンチウイルスベクターの構築方法は以下の通りである。
(1)完全培地:予熱した新鮮な培地を取り、10%FBS +5ml Pen-Srepを入れ、上下反転して均一に混合した。
一.イオン交換クロマトグラフィーによって組換えレンチウイルスベクターを精製した(図8に示す)。
(1)24ウェルプレートを取って293T細胞を接種した。各ウェルの細胞は5×104個で、加えられた培地の体積は500μlで、異なる種類の細胞の生長速度は異なり、ウイルス感染時の細胞融合率は40%〜60%であった。
IU ml-1 = (C ×N× D×1000)/V
ここで、
C = 1ゲノムあたり組み込まれたウイルスのコピー数
N = 感染時の細胞数(約1×105)
D = ウイルスベクターの希釈倍率
V = 入れた希釈ウイルスの体積
(1)内毒素使用標準品は15EU/本であった。
サンプル管に0.1mlのサンプルを加え、表5に示す希釈比率で、37±1℃の水浴(またはインキュベーター)で60±1min保温した。
(1)実験前の3日は、細胞サンプルを無抗生物質培地で培養した。
一.CAR遺伝子の細胞レベルの発現測定:
(1)組換えレンチウイルスベクターlvCARbcma-1453〜lvCARbcma-1460および対照ウイルスMOCKでPBMC細胞に感染させた後、細胞を収集してRT-PCRによってCARのmRNA転写レベルの測定を行い、CAR遺伝子の発現を検証したが、CARのmRNA転写レベルが向上すると、CAR遺伝子の転写レベルの発現に成功したことになる。
二.PD-1ノックダウン効果の評価(PD-1 mRNA転写レベル)
(1)それぞれBCMA-K562細胞とPBMC細胞を培養した。
(1)それぞれBCMA-PDL1-K562細胞とPBMC細胞を培養した。
(2)実験開始前の4日は、MOI=15のlvCARbcma-1453〜lvCARbcma-1460のウイルスでPBMC細胞に感染させ、72-96h培養した後、実験を開始した。
(3)標的細胞(BCMA-PDL1-K562)4x105細胞とエフェクター細胞(CART細胞)2.8x106細胞を収集し、800gで6min遠心分離し、上清を捨てた。
(5)工程(4)を1回繰り返した。
(6)700μlの培地(1640培地+10% FBS)でエフェクター細胞を再懸濁させ、2mlの培地(1640培地+10% FBS)で標的細胞を再懸濁させた。
(8)250×gで5minプレート遠心分離した。
(10)250×gで5minプレート遠心分離した。
(11)各ウェルの50μl上清を取って新たな96ウェルプレートに加え、そして各ウェルに50μlの基質溶液を加えた(光を避けた操作)。
(13)各ウェルに50uLの停止液を加えた。
(14)マイクロプレートによって490nmにおける吸光度を測定した。
殺傷効率= (実験ウェル−エフェクター細胞ウェル−標的細胞ウェル)/(標的細胞最大ウェル−標的細胞ウェル)×100%
Claims (15)
- ヒトPD-1をノックダウンするsiRNAであって、配列番号41および配列番号42で示されるヌクレオチド配列の1対であるsiRNA。
- 腫瘍の免疫逃避機序を解消または軽減する薬物の製造における請求項1に記載のsiRNAの使用。
- 請求項1に記載のsiRNAをコードする配列を含む組換え発現ベクター。
- 前記発現ベクターはレンチウイルス発現ベクター、レトロウイルス発現ベクター、アデノウイルス発現ベクター、アデノ随伴ウイルス発現ベクターまたはプラスミドであることを特徴とする請求項3に記載の組換え発現ベクター。
- 前記のレンチウイルス発現ベクターは、配列番号2で示されるプラスミド複製のための原核レプリコンpUC Ori配列、配列番号1で示される目的菌株の大量増幅のためのアンピシリン耐性遺伝子含有AmpR配列、配列番号3で示される真核細胞内における複製を増強するためのウイルスレプリコンSV40 Ori配列、レンチウイルスパッケージングのためのレンチウイルスパッケージングのシスエレメント、配列番号11で示される真核細胞における緑色蛍光タンパク質の発現のためのZsGreen1緑色蛍光タンパク質のコード遺伝子、配列番号12で示されるタンパク質の共転写発現のためのIRESリボソーム結合配列、配列番号15で示されるキメラ抗原受容体遺伝子の真核転写のためのヒトEF1αプロモーター、認識、伝達、開始が一体化した第二世代CARまたは第三世代CARを組み立てるための抗BCMAキメラ抗原受容体のコード遺伝子、配列番号13で示される遺伝子組換えの発現効率を増強するためのeWPRE増強型ウッドチャックB型肝炎ウイルス転写後調節エレメント、配列番号14で示される細胞内におけるsiRNAの転写のためのヒトRNAポリメラーゼIIIプロモーターhU6を含むことを特徴とする請求項4に記載の組換え発現ベクター。
- 前記レンチウイルスパッケージングのシスエレメントは、第二世代のレンチウイルスベクターを使用し、配列番号5で示されるレンチウイルス5'末端LTR、配列番号6で示されるレンチウイルス3'末端自己不活性化LTR、配列番号7で示されるGagシスエレメント、配列番号8で示されるRREシスエレメント、配列番号9で示されるenvシスエレメント、配列番号10で示されるcPPTシスエレメントを含むことを特徴とする請求項5に記載の組換え発現ベクター。
- 前記レンチウイルスパッケージングのシスエレメントは、第三世代のレンチウイルスベクターを使用し、配列番号5で示されるレンチウイルス5'末端LTR、配列番号6で示されるレンチウイルス3'末端自己不活性化LTR、配列番号7で示されるGagシスエレメント、配列番号8で示されるRREシスエレメント、配列番号9で示されるenvシスエレメント、配列番号10で示されるcPPTシスエレメント、および配列番号4で示されるRSVプロモーターを含むことを特徴とする請求項5に記載の組換え発現ベクター。
- 前記eWPRE増強型ウッドチャックB型肝炎ウイルス転写後調節エレメントは、6つのヌクレオチドの増強突然変異g.396G>A、g.397C>T、g.398T>C、g.399G>A、g.400A>T、およびg.411A>Tを有することを特徴とする請求項5に記載の組換え発現ベクター。
- 前記抗BCMAキメラ抗原受容体のコード遺伝子は、順に直列に接続する配列番号16で示されるCD8 leaderキメラ受容体シグナルペプチドをコードする配列、配列番号17で示されるBCMAの1本鎖抗体軽鎖VLをコードする配列、配列番号18で示されるOptimal Linker Cをコードする配列、配列番号19で示されるBCMAの1本鎖抗体重鎖VHをコードする配列、配列番号20で示されるCD8 Hingeキメラ受容体ヒンジをコードする配列、配列番号21で示されるCD8 Transmembraneキメラ受容体膜貫通領域をコードする配列、配列番号22で示されるCD137キメラ受容体共刺激因子をコードする配列、および配列番号23で示されるTCRキメラ受容体T細胞活性化ドメインをコードする配列を含むことを特徴とする請求項5に記載の組換え発現ベクター。
- 前記抗BCMAキメラ抗原受容体のコード遺伝子は、順に直列に接続する配列番号16で示されるCD8 leaderキメラ受容体シグナルペプチドをコードする配列、配列番号17で示されるBCMAの1本鎖抗体軽鎖VLをコードする配列、配列番号18で示されるOptimal Linker Cをコードする配列、配列番号19で示されるBCMAの1本鎖抗体重鎖VHをコードする配列、配列番号20で示されるCD8 Hingeキメラ受容体ヒンジをコードする配列、配列番号21で示されるCD8 Transmembraneキメラ受容体膜貫通領域をコードする配列、配列番号24示されるCD28キメラ受容体共刺激因子をコードする配列、配列番号22で示されるCD137キメラ受容体共刺激因子をコードする配列、および配列番号23で示されるTCRキメラ受容体T細胞活性化ドメインをコードする配列を含むことを特徴とする請求項5に記載の組換え発現ベクター。
- 請求項1に記載のsiRNAをコードする配列を含むレンチウイルス発現ベクターの構築方法であって、
アンピシリン耐性遺伝子含有AmpR配列(配列番号1で示される)、原核レプリコンpUC Ori配列(配列番号2で示される)、ウイルスレプリコンSV40 Ori配列(配列番号3で示される)、レンチウイルスパッケージングのためのレンチウイルスパッケージングのシスエレメント、ZsGreen1緑色蛍光タンパク質のコード遺伝子(配列番号11で示される)、IRESリボソーム結合配列(配列番号12で示される)、eWPRE増強型ウッドチャックB型肝炎ウイルス転写後調節エレメント(配列番号13で示される)、ヒトRNAポリメラーゼIIIプロモーターhU6(配列番号14で示される)をレンチウイルス骨格プラスミドに組み込む工程(1)と、
ヒトEF1αプロモーター(配列番号15で示される)、認識、伝達、開始が一体化した第二世代CARまたは第三世代CARを組み立てるための抗BCMAキメラ抗原受容体のコード遺伝子を第二世代CARまたは第三世代CARの設計態様に組み立て、酵素切断、連結、組換え反応を経てレンチウイルス骨格プラスミドにクローニングし、第二世代CARまたは第三世代CARの設計の組換えレンチウイルスプラスミドを得る工程(2)と、
上記siRNAをコードする配列および配列番号55と配列番号56で示される陰性対照配列をコードする配列を、それぞれ工程(2)で得られた組換えレンチウイルスプラスミドにクローニングし、IL-1ノックダウン組換えレンチウイルスプラスミドを得る工程(3)と、
工程(3)で得られた組換えレンチウイルスプラスミドをそれぞれレンチウイルスパッケージングプラスミドおよび膜タンパク質プラスミドとHEK293T/17細胞に共形質移入させ、HEK293T/17細胞において遺伝子の転写・発現を行わせた後、パッケージングが成功した組換えレンチウイルスベクターが細胞培養上清に放出され、組換えレンチウイルスベクターを含む上清液を収集する工程(4)と、
得られた組換えレンチウイルス上清は吸引ろ過、吸着、溶離のイオン交換手段によって精製し、それぞれ組換えレンチウイルスベクターを得る工程(5)と、
を含む構築方法。 - 工程(5)において、前記吸引ろ過ステップは、上清体積を200ml〜2000mlに、真空度を-0.5MPA〜-0.9MPAに抑え、穴詰まりによるベクターの損失を防ぎ、前記吸着ステップは、溶液のpH値を6〜8に抑え、pHの変化によるベクターの不活性化を防止し、前記溶離ステップは溶離液のイオン強度を0.5M〜1.0Mに抑え、イオン強度の変化による溶離の不完全またはベクターの不活性化を防ぐことを特徴とする請求項11に記載の構築方法。
- CAR-Tによる腫瘍の治療過程において腫瘍の免疫逃避機序を解消または軽減する薬物の製造における請求項3〜10のいずれかに記載の組換え発現ベクターの使用。
- 請求項3に記載の請求項1に記載のsiRNAをコードする配列を含む組換え発現ベクターにより形質移入されたT細胞である、CAR-T細胞。
- 多発性骨髄腫、膵臓腺癌、脳膠細胞腫、骨髄腫の治療薬の製造における請求項14に記載のCAR-T細胞の使用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021128277A JP7264522B2 (ja) | 2016-12-08 | 2021-08-04 | ヒトPD-1をノックダウンしたsiRNA、組換え発現CAR-Tベクターおよびその構築方法と使用 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611123283.4 | 2016-12-08 | ||
CN201611123283.4A CN107058315B (zh) | 2016-12-08 | 2016-12-08 | 敲减人PD-1的siRNA、重组表达CAR-T载体及其构建方法和应用 |
PCT/CN2017/110653 WO2018103501A1 (zh) | 2016-12-08 | 2017-11-13 | 敲减人PD-1的siRNA、重组表达CAR-T载体及其构建方法和应用 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021128277A Division JP7264522B2 (ja) | 2016-12-08 | 2021-08-04 | ヒトPD-1をノックダウンしたsiRNA、組換え発現CAR-Tベクターおよびその構築方法と使用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019534711A JP2019534711A (ja) | 2019-12-05 |
JP6930762B2 true JP6930762B2 (ja) | 2021-09-01 |
Family
ID=59619402
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019538555A Active JP6930762B2 (ja) | 2016-12-08 | 2017-11-13 | ヒトPD−1をノックダウンしたsiRNA、組換え発現CAR−Tベクターおよびその構築方法と使用 |
JP2021128277A Active JP7264522B2 (ja) | 2016-12-08 | 2021-08-04 | ヒトPD-1をノックダウンしたsiRNA、組換え発現CAR-Tベクターおよびその構築方法と使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021128277A Active JP7264522B2 (ja) | 2016-12-08 | 2021-08-04 | ヒトPD-1をノックダウンしたsiRNA、組換え発現CAR-Tベクターおよびその構築方法と使用 |
Country Status (6)
Country | Link |
---|---|
US (1) | US11242530B2 (ja) |
EP (1) | EP3505631A4 (ja) |
JP (2) | JP6930762B2 (ja) |
KR (1) | KR102266751B1 (ja) |
CN (1) | CN107058315B (ja) |
WO (1) | WO2018103501A1 (ja) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107058315B (zh) | 2016-12-08 | 2019-11-08 | 上海优卡迪生物医药科技有限公司 | 敲减人PD-1的siRNA、重组表达CAR-T载体及其构建方法和应用 |
CN109321587B (zh) * | 2017-09-21 | 2022-06-28 | 华东师范大学 | 一种acat1基因干扰的嵌合抗原受体t细胞 |
CN109593721B (zh) * | 2017-09-30 | 2022-11-01 | 亘喜生物科技(上海)有限公司 | 具有自杀基因开关的靶向人间皮素的工程化免疫细胞 |
US11246908B2 (en) * | 2018-01-10 | 2022-02-15 | The Johns Hopkins University | Compositions comprising albumin-FMS-like tyrosine kinase 3 ligand fusion proteins and uses thereof |
CN108913690B (zh) * | 2018-07-11 | 2020-01-14 | 新乡医学院 | Pd-1特异性干扰序列、质粒、减毒沙门氏菌及在抗肿瘤的应用 |
US20220380774A1 (en) * | 2019-05-20 | 2022-12-01 | Olix Pharmaceuticals, Inc. | Asymmetric sirna inhibiting expression of pd-1 |
WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
CN111206051A (zh) * | 2019-12-11 | 2020-05-29 | 浙江大学医学院附属第一医院 | Runx3过表达、pd-1敲减的car表达载体的构建方法和应用 |
AU2021306613A1 (en) | 2020-07-07 | 2023-02-02 | BioNTech SE | Therapeutic RNA for HPV-positive cancer |
CN112481304A (zh) * | 2020-09-27 | 2021-03-12 | 镇江维根生物科技有限公司 | 一种多功能病毒载体的构建和应用 |
CN112239759A (zh) * | 2020-10-28 | 2021-01-19 | 重庆斯德姆生物技术有限公司 | 用于敲低PD1基因表达的microRNA及其嵌合抗原受体-T/NK细胞的构建 |
CN112575093A (zh) * | 2020-12-15 | 2021-03-30 | 北京艺妙神州医药科技有限公司 | 一种用于检测过继性免疫细胞的引物探针组合物和试剂盒 |
TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性rna |
WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
TW202304506A (zh) | 2021-03-25 | 2023-02-01 | 日商安斯泰來製藥公司 | 涉及抗claudin 18.2抗體的組合治療以治療癌症 |
AU2022312698A1 (en) | 2021-07-13 | 2024-01-25 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
WO2023057534A1 (en) | 2021-10-06 | 2023-04-13 | Genmab A/S | Multispecific binding agents against pd-l1 and cd137 in combination |
TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
WO2023083439A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Tlr7 agonist and combinations for cancer treatment |
WO2023169491A1 (zh) * | 2022-03-10 | 2023-09-14 | 苏州易慕峰生物科技有限公司 | 细胞黏附能力下调的免疫细胞及其医药用途 |
WO2023218046A1 (en) | 2022-05-12 | 2023-11-16 | Genmab A/S | Binding agents capable of binding to cd27 in combination therapy |
WO2023228968A1 (ja) * | 2022-05-25 | 2023-11-30 | 国立大学法人東海国立大学機構 | ポリヌクレオチド |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5637481A (en) * | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
JP4311003B2 (ja) * | 2002-12-02 | 2009-08-12 | アイシン精機株式会社 | 原核生物の遺伝子発現解析方法 |
SG10201510092QA (en) * | 2010-12-09 | 2016-01-28 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
UA112434C2 (uk) * | 2011-05-27 | 2016-09-12 | Ґлаксо Ґруп Лімітед | Антигензв'язувальний білок, який специфічно зв'язується з всма |
TWI775096B (zh) * | 2012-05-15 | 2022-08-21 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
WO2014055771A1 (en) * | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
HUE047487T2 (hu) * | 2013-02-15 | 2020-04-28 | Univ California | Kiméra antigénreceptor és eljárások alkalmazására |
EP3033150A4 (en) * | 2013-08-13 | 2017-06-28 | Bionumerik Pharmaceuticals, Inc. | Administration of karenitecin for the treatment of advanced ovarian cancer, including chemotherapy-resistant and/or the mucinous adenocarcinoma sub-types |
CA2927543C (en) * | 2013-10-15 | 2021-07-20 | The California Institute For Biomedical Research | Peptidic chimeric antigen receptor t cell switches and uses thereof |
RU2744194C2 (ru) * | 2013-12-02 | 2021-03-03 | Фио Фармасьютикалс Корп | Иммунотерапия рака |
CN104711253A (zh) * | 2013-12-11 | 2015-06-17 | 深圳先进技术研究院 | 一种用于抗体表达的表达框、表达载体、含该载体的宿主细胞及其制备方法和应用 |
JP6779785B2 (ja) * | 2013-12-19 | 2020-11-04 | ノバルティス アーゲー | ヒトメソテリンキメラ抗原受容体およびその使用 |
CN103820454B (zh) * | 2014-03-04 | 2016-03-30 | 上海金卫生物技术有限公司 | CRISPR-Cas9特异性敲除人PD1基因的方法以及用于特异性靶向PD1基因的sgRNA |
US20170081411A1 (en) * | 2014-03-15 | 2017-03-23 | Novartis Ag | Regulatable chimeric antigen receptor |
BR112017001183A2 (pt) * | 2014-07-21 | 2017-11-28 | Novartis Ag | tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado |
CA2958200A1 (en) * | 2014-08-14 | 2016-02-18 | Novartis Ag | Treatment of cancer using a gfr alpha-4 chimeric antigen receptor |
WO2016057933A1 (en) * | 2014-10-10 | 2016-04-14 | Global Biopharma, Inc. | Methods for treating and/or preventing a tumor growth, invasion and/or metastasis |
MA41346A (fr) * | 2015-01-12 | 2017-11-21 | Juno Therapeutics Inc | Eléments régulateurs post-transcriptionnels d'hépatite modifiée |
WO2016126608A1 (en) * | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
WO2016132122A1 (en) * | 2015-02-17 | 2016-08-25 | University Of Edinburgh | Assay construct |
US9828601B2 (en) * | 2015-02-27 | 2017-11-28 | Idera Pharmaceuticals, Inc. | Compositions for inhibiting checkpoint gene expression and uses thereof |
CN107921147B (zh) * | 2015-05-05 | 2021-12-24 | 江苏命码生物科技有限公司 | 一种新的前体miRNA及其在肿瘤治疗中的应用 |
CN105331585A (zh) * | 2015-11-13 | 2016-02-17 | 科济生物医药(上海)有限公司 | 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞 |
CN105602992B (zh) * | 2016-03-17 | 2019-06-21 | 上海优卡迪生物医药科技有限公司 | 一种基于复制缺陷性重组慢病毒的car-t转基因载体及其构建方法和应用 |
CN105949317B (zh) * | 2016-04-12 | 2019-07-02 | 上海优卡迪生物医药科技有限公司 | 抗cd20嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用 |
CN105777911B (zh) * | 2016-04-12 | 2019-07-02 | 上海优卡迪生物医药科技有限公司 | 抗bcma嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用 |
CN105837693A (zh) * | 2016-05-30 | 2016-08-10 | 李斯文 | 一种基于bcma的抗原嵌合受体及其制备方法和应用 |
GB201609597D0 (en) * | 2016-06-01 | 2016-07-13 | Univ Sheffield | Therapy |
CN106191062B (zh) * | 2016-07-18 | 2019-06-14 | 广东华南疫苗股份有限公司 | 一种tcr-/pd-1-双阴性t细胞及其构建方法 |
US10385319B2 (en) * | 2016-09-08 | 2019-08-20 | The Governement of the United States of America, as represented by the Secretary of Homeland Security | Modified foot-and-mouth disease virus 3C proteases, compositions and methods thereof |
CN107058315B (zh) * | 2016-12-08 | 2019-11-08 | 上海优卡迪生物医药科技有限公司 | 敲减人PD-1的siRNA、重组表达CAR-T载体及其构建方法和应用 |
-
2016
- 2016-12-08 CN CN201611123283.4A patent/CN107058315B/zh active Active
-
2017
- 2017-11-13 US US16/331,147 patent/US11242530B2/en active Active
- 2017-11-13 JP JP2019538555A patent/JP6930762B2/ja active Active
- 2017-11-13 EP EP17878422.9A patent/EP3505631A4/en active Pending
- 2017-11-13 KR KR1020197007198A patent/KR102266751B1/ko active IP Right Grant
- 2017-11-13 WO PCT/CN2017/110653 patent/WO2018103501A1/zh unknown
-
2021
- 2021-08-04 JP JP2021128277A patent/JP7264522B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
WO2018103501A1 (zh) | 2018-06-14 |
EP3505631A1 (en) | 2019-07-03 |
US11242530B2 (en) | 2022-02-08 |
KR102266751B1 (ko) | 2021-06-23 |
CN107058315A (zh) | 2017-08-18 |
US20190218559A1 (en) | 2019-07-18 |
EP3505631A4 (en) | 2019-10-09 |
KR20190038643A (ko) | 2019-04-08 |
JP2021184728A (ja) | 2021-12-09 |
JP7264522B2 (ja) | 2023-04-25 |
CN107058315B (zh) | 2019-11-08 |
JP2019534711A (ja) | 2019-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6930762B2 (ja) | ヒトPD−1をノックダウンしたsiRNA、組換え発現CAR−Tベクターおよびその構築方法と使用 | |
JP6996779B2 (ja) | ヒト由来インターロイキン6のsiRNA、組換え発現CAR-Tベクターおよびその構築方法と使用 | |
JP6736109B2 (ja) | Pdl1がブロッキングされた免疫逃避を抑制するためのcar−t遺伝子組換えベクターおよびその構築方法と使用 | |
JP6783009B2 (ja) | Il6rがブロッキングされたcrsを緩和するためのcar−t遺伝子組換えベクターおよびその構築方法と使用 | |
CN106967685B (zh) | 共表达抗EGFRvIII嵌合抗原受体和免疫检查点抑制分子的转基因淋巴细胞及其用途 | |
WO2018223600A1 (zh) | Octs-car双靶向嵌合抗原受体、编码基因、重组表达载体及其构建和应用 | |
JP6890831B2 (ja) | Hiv予備免疫化および免疫療法 | |
WO2021197391A1 (zh) | 一种制备经修饰的免疫细胞的方法 | |
CN106967681B (zh) | 治疗脑胶质母细胞瘤的治疗组合物 | |
WO2019223226A1 (zh) | 改良型抗cd19 car-t细胞 | |
KR20210063348A (ko) | 개선된 치료용 t 세포 | |
CN108342363B (zh) | 共表达抗msln嵌合抗原受体和免疫检查点抑制分子的转基因淋巴细胞及其用途 | |
WO2018218877A1 (zh) | 一种基于octs技术的恶性胶质瘤car-t治疗载体及其构建方法和应用 | |
CN107034193B (zh) | 治疗b细胞白血病及b细胞淋巴瘤的治疗组合物 | |
WO2018006880A1 (zh) | 重组免疫检查点受体及免疫检查点抑制分子的共表达及应用 | |
CN108342361B (zh) | 治疗间质素阳性肿瘤的治疗组合物 | |
WO2018218879A1 (zh) | 一种基于octs技术的胰腺癌、恶性间皮瘤car-t治疗载体及其构建方法和应用 | |
WO2020019983A1 (zh) | 一种用于治疗肿瘤的基因工程细胞 | |
WO2007142241A1 (ja) | 抗cd38抗体を細胞表面に有する免疫担当細胞 | |
WO2020025039A1 (zh) | 表达嵌合抗原受体的t细胞、该嵌合抗原相关表达载体以及它们的应用 | |
CN114369622A (zh) | 同时靶向cd7和cd19的双特异通用型car-t细胞及其制备方法 | |
CN112521515B (zh) | Cd19和cd10双靶点嵌合抗原受体及其应用 | |
US20210155928A1 (en) | Rna-aided immunotherapeutics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190402 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200303 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200602 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201006 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210104 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210323 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210616 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210706 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210804 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6930762 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |